Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.
MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2- to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12 micrograms/ml; S. aureus, oxacillin resistant, 0.25 micrograms/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25 micrograms/ml; and CNS, oxacillin resistant, 2 micrograms/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to greater than 128 micrograms/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.
Jones
R N
RN
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
Goldstein
F W
FW
Zhou
X Y
XY
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001441:Bacteroides fragilis / Q000187:drug effects; D005602:France; D006020:Glycopeptides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D012310:Ristocetin / Q000031:analogs & derivatives; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D017334:Teicoplanin; D014481:United States; D014640:Vancomycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; C068029:MDL 62873; D012310:Ristocetin; D017334:Teicoplanin; D014640:Vancomycin